Treatment of Chronic Lymphocytic Leukemia

Initial Management Approach

The American Society of Hematology recommends a "watch and wait" strategy for early-stage asymptomatic CLL patients, with regular monitoring of blood counts and clinical examinations every 3 months 1
Treatment should only be initiated when patients develop criteria for "active disease" according to international guidelines 1

The European Society for Medical Oncology indicates that B symptoms, such as fever, night sweats, and weight loss, are an indication for treatment 1
Cytopenias not caused by autoimmune phenomena are also an indication for treatment, as stated by the National Comprehensive Cancer Network 1
Symptoms or complications from lymphadenopathy, splenomegaly, or hepatomegaly require treatment, according to the American College of Physicians 1
Progressive lymphocytosis with lymphocyte doubling time <6-12 months is an indication for treatment, as recommended by the International Workshop on Chronic Lymphocytic Leukemia 1
Autoimmune complications, such as anemia or thrombocytopenia, poorly responsive to corticosteroids, require treatment, as stated by the European Hematology Association 3

FISH testing for chromosomal abnormalities, particularly del(17p) and TP53 mutations, is essential for treatment selection, according to the National Cancer Institute 1
Immunoglobulin heavy chain variable region (IGHV) mutational status helps predict treatment response, as recommended by the American Society of Clinical Oncology 1
Patient fitness assessment, including age, comorbidities, and renal function, guides treatment choice, as stated by the European Society for Medical Oncology 1

For physically fit patients without del(17p)/TP53 mutations, the American College of Physicians recommends fludarabine and cyclophosphamide (FC) as initial treatment, which induces higher complete remission rates and longer progression-free survival than chlorambucil or purine analog monotherapy 4, 2
The addition of rituximab (FCR) has shown improved survival outcomes, as stated by the National Comprehensive Cancer Network 2
Time-limited therapy with venetoclax (BCL2 inhibitor) plus obinutuzumab for 12 cycles is preferred, especially for patients with mutated IGHV, according to the European Hematology Association 1

If relapse occurs >12 months after initial therapy, the first-line treatment may be repeated, as recommended by the International Workshop on Chronic Lymphocytic Leukemia 3
For early relapse (<12 months) or refractory disease, switching to an alternative class of agents is recommended, such as fludarabine, FC, or cladribine after chlorambucil, as stated by the American Society of Hematology 3
Options include fludarabine combinations with cyclophosphamide and/or mitoxantrone plus monoclonal antibodies in fludarabine-refractory patients, as recommended by the National Cancer Institute 3

Allogeneic stem cell transplantation is the only curative therapy for high-risk CLL [del(17p), del(11q)] and/or refractory disease, as stated by the European Society for Medical Oncology 3
Patients with del(17p) frequently do not respond to conventional chemotherapy with fludarabine or FC, according to the American College of Physicians 3
Treatment decisions should be based on disease activity rather than absolute lymphocyte count, as recommended by the American Society of Clinical Oncology 7
Monitor for tumor lysis syndrome risk, which is high with intensive chemotherapy, as stated by the National Comprehensive Cancer Network 6